Eli Lilly raised its full-year 2026 sales forecast after reporting third-quarter earnings and revenue that beat analyst estimates. The company now expects revenue of $91 billion to $92 billion, up from its previous guidance of $85 billion to $87 billion. Its shares rose about 7% on Thursday.

Demand for Zepbound and Mounjaro drove the results. Mounjaro's worldwide revenue rose 65% to $10.72 billion for the quarter, with U.S. sales of about $5 billion, according to the report. Analysts had expected $10.10 billion in worldwide sales. Zepbound posted $5.35 billion in revenue, up 49% from a year earlier, compared with analyst expectations of $5.09 billion.

The new obesity pill Foundayo, which launched in the U.S. in April, fell short of expectations. It generated $184 million in third-quarter sales, below analyst forecasts of about $229 million, according to StreetAccount estimates cited in the report. The company said U.S. prescriptions for Foundayo doubled from the previous quarter.

Lilly's adjusted full-year earnings forecast is $35 to $36 per share, slightly below its previous outlook of $35.50 to $36.50. The company said it raised underlying profit guidance by $4.07 per share at the midpoint, but that increase is offset by $4.57 per share in charges tied to deals made in the quarter.

According to an earnings presentation cited in the report, Lilly held 63% of the U.S. obesity and diabetes drug market in the third quarter, while Novo Nordisk held 36.6%. CEO Dave Ricks told CNBC that he estimates 3% to 10% of eligible patients in the U.S. currently access obesity care. "This is a program that's really working," Ricks said of Medicare's temporary pilot covering GLP-1 drugs for weight loss, which began in July.